Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $7.30

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been given an average recommendation of “Hold” by the five research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $7.30.

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Friday, January 10th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $8.00 price target on the stock. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price on the stock. Finally, StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Esperion Therapeutics Stock Up 2.3 %

Shares of Esperion Therapeutics stock opened at $2.26 on Friday. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94. The company’s 50-day simple moving average is $2.47 and its 200-day simple moving average is $2.18. The firm has a market cap of $445.30 million, a price-to-earnings ratio of -3.53, a price-to-earnings-growth ratio of 0.17 and a beta of 1.03.

Institutional Trading of Esperion Therapeutics

Several large investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in shares of Esperion Therapeutics by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 2,069,117 shares of the biopharmaceutical company’s stock valued at $3,414,000 after purchasing an additional 19,588 shares during the last quarter. Eaton Financial Holdings Company LLC acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at approximately $73,000. Barclays PLC grew its position in shares of Esperion Therapeutics by 99.6% in the third quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 154,509 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after purchasing an additional 171,609 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at approximately $606,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.